Trichostatin A - Vanda Pharmaceuticals

Drug Profile

Trichostatin A - Vanda Pharmaceuticals

Alternative Names: VTR-297

Latest Information Update: 14 Nov 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Vanda Pharmaceuticals
  • Class Antibacterials; Antineoplastics; Small molecules
  • Mechanism of Action Histone deacetylase inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • Preclinical Haematological malignancies

Most Recent Events

  • 07 Nov 2017 US FDA approves IND application for Trichostatin A in Haematological malignancies
  • 07 Nov 2017 Vanda Pharmaceuticals plans a phase I 1101 dose-escalation trial for Haematological malignancies in USA in the first half of 2018
  • 15 Feb 2017 Vanda Pharmaceuticals plans to file an IND application with the FDA in USA for Haematological malignancies
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top